FDA
-
-
-
-
-
-
-
H.C. Wainwright Reiterates Neutral Rating on aTyr Pharma (ATYR): "viewing the upcoming 1Q26 Type C meeting with the FDA as a critical catalyst"
-
-
-
-
-
-
-
H.C. Wainwright Downgrades aTyr Pharma (ATYR) to Neutral
-
-
-
-
-
-
-
H.C. Wainwright Reiterates Buy Rating on aTyr Pharma (ATYR)
-
-
-
-
-
-
325,894 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

